APTX

Across TCGA pan-cancer cohorts, APTX mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated APTX data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher APTX mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated APTX expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where APTX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.808	0.294	.019	10	view →
CCRCC	DFS	Median	II,III,IV	0.750	0.467	.014	3	view →
LSCC	DFS	Tertile	II,III,IV	0.824	0.576	.036	2	view →
GBM	OS	Quartile	All	0.611	0.212	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

APTX–LUAD (OS)

Open the LUAD breakdown →